Omar Abdel-Rahman1, Hesham ElHalawani1, Mona Fouad2. 1. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 2. Medical Microbiology & Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Abstract
BACKGROUND: We performed a meta-analysis of the risk of endocrine adverse events associated with immune check point inhibitors. METHODS: Eligible studies included randomized trials of cancer patients on immune checkpoint inhibitors; describing events of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency. RESULTS: A total of ten clinical trials were eligible for the meta-analysis. The relative risk of all-grade hypothyroidism, hyperthyroidism, hypophyisitis and adrenal insufficiency were 8.26 (95% CI: 4.67-14.62; p < 0.00001), 5.48 (95% CI: 1.33-22.53; p = 0.02); 22.03 (95% CI: 8.52-56.94; p < 0.00001), 3.87 (95% CI: 1.12-13.41; p = 0.03), respectively. CONCLUSION: Our meta-analysis has demonstrated that the use of immune check point inhibitors is associated with an increased risk of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency compared with control.
BACKGROUND: We performed a meta-analysis of the risk of endocrine adverse events associated with immune check point inhibitors. METHODS: Eligible studies included randomized trials of cancerpatients on immune checkpoint inhibitors; describing events of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency. RESULTS: A total of ten clinical trials were eligible for the meta-analysis. The relative risk of all-grade hypothyroidism, hyperthyroidism, hypophyisitis and adrenal insufficiency were 8.26 (95% CI: 4.67-14.62; p < 0.00001), 5.48 (95% CI: 1.33-22.53; p = 0.02); 22.03 (95% CI: 8.52-56.94; p < 0.00001), 3.87 (95% CI: 1.12-13.41; p = 0.03), respectively. CONCLUSION: Our meta-analysis has demonstrated that the use of immune check point inhibitors is associated with an increased risk of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency compared with control.
Authors: Jason M Redman; Logan P Rhea; Lisa Cordes; Helen Owens; Ravi A Madan; Marijo Bilusic; James L Gulley; Jung-Min Lee; William L Dahut; Fatima Karzai Journal: Clin Genitourin Cancer Date: 2019-02-14 Impact factor: 2.872
Authors: F Guaraldi; R La Selva; M T Samà; V D'Angelo; D Gori; P Fava; M T Fierro; P Savoia; E Arvat Journal: J Endocrinol Invest Date: 2017-10-17 Impact factor: 4.256